Amgen/KK’s Atopic Dermatitis Deal Shows OX40’s Allure, But Market Still Tough
Amgen will pay $400m upfront and up to $850m in milestones
Amgen said Phase II data are planned for the EADV 2021 meeting, but KHK4083 will need a strong showing.
You may also be interested in...
Commercial EVP Murdo Gordon said launching sotorasib during the pandemic is a tougher challenge than encouraging doctors to screen lung cancer patients for KRAS G12C mutations and raising patient awareness.
The company showed improvement on an endpoint used in several Phase III studies of JAK inhibitors, but with a potentially better safety profile.
Another UK biotech has been swallowed up by a big pharma with Sanofi acquiring the Cambridge-based firm in a deal that could be worth almost $1.5bn.